Since the alteration in the laminin-binding glycan of α-dystroglycan plays a crucial role in cancer development and progression, increasing expression of matriglycan could be a novel therapeutic approach for cancers, as demonstrated in breast cancer cells treated with ribitol-enhanced matriglycan [27]. This evidence concerns the gene DAG1 and cancer.